Intellect Neurosciences Inc. (fka ILNS)

[Zilla]

Long post but well worth understanding. ELN and WYE and the two other unnamed "another top tier pharmaceutical company/Top Tier Global Pharmaceutical Company"
My speculation:I wonder if JNJ and PFE took a peek and realized what ILNS has and then JUMPED to get ELN and WYE?!?

From ILNS website: 11/21/08 shareholders letter... "We granted a non-exclusive, worldwide, royalty-bearing license to our ANTISENILIN® AD monoclonal antibody platform to Wyeth and Elan Pharmaceuticals. The license grants rights to Wyeth and Elan under Intellect's patents with respect to the development and sale of Bapineuzumab, a monoclonal antibody intended to treat AD. Wyeth and Elan are currently testing Bapineuzumab in several thousand Alzheimer's patients in a Phase 3 clinical trial. If successful, the drug could be launched early in 2012. Bapineuzumab has enormous sales potential as the first disease modifying drug in the field of AD and Intellect is entitled to a significant royalties on any future sales. The grant of this first license under our ANTISENILIN® patents was of great significance because it validated and established the value of our technology and of our business model that calls for broad licensing of our technology.
We recently granted an option to acquire a similar non-exclusive license to the ANTISENILIN® patents to another top tier pharmaceutical company that is developing its own monoclonal antibody for AD. The drug is currently being tested in humans. We are entitled to an upfront payment if and when this pharmaceutical company exercises the option in the first quarter of 2009 as well as patent milestones and royalties from sales. We are in discussions to grant additional licenses to other major companies."
AND THEN...1/7/09 "Intellect Neurosciences, Inc. Grants Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent ApplicationsIntellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications"

And our own drug...OXIGON

"OXIGON® is a clinical stage drug candidate being developed by the company as a promising potential disease-modifying drug for Alzheimer's disease based on its unique combination of pharmacological properties. The drug has the potential to protect the brain and other tissues against oxidative stress and in addition appears to stabilize the less toxic soluble forms of beta-amyloid preventing aggregation into more toxic forms."

Yes it's long, but it's a start for DD. I've been following ELN since it fell from above 35 and Bapineuzumab was the reason why I liked ELN. now I've found a way to have a piece of that Bapineuzumab pie without having to spend as much as PFE and JNJ. :)